Research Article

Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis

Chun-yan Sun†, Jun-ying Li*, Zhang-bo Chu, Lu Zhang, Lei Chen and Yu Hu

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Correspondence: Yu Hu (dr_huyu@126.com)

Multiple myeloma (MM) is a B-cell neoplasm with a high incidence of relapse. Bortezomib has been extensively studied for the maintenance treatment of MM. Here, we carried out a meta-analysis to determine the efficacy and safety of maintenance therapy with bortezomib. We searched for clinical trials in PubMed (Medline), Embase (OVID), and the Cochrane Library. Two randomized controlled trials (RCTs) enrolling a total of 1338 patients were included. Bortezomib maintenance statistically significantly improved both progression-free survival (PFS) (hazard ratio (HR) 0.67, 95% confidence interval (CI) = 0.51 to 0.87, \(p=0.003\)) and overall survival (OS) (HR = 0.75 therapy, 95% CI = 0.63 to 0.89, \(p=0.001\)) more than did non-bortezomib maintenance therapy. Our analysis revealed higher incidence of neutropenia (risks ratios (RR) = 1.39; 95% CI = 1.08 to 1.79), peripheral neuropathy (PN) (RR = 2.23; 95% CI = 1.38 to 3.61, \(p=0.001\)), and cardiologic events (RR = 1.91; 95% CI = 1.12 to 3.28, \(p=0.02\)) in patients with bortezomib maintenance therapy. Our meta-analysis demonstrates OS and PFS benefits of bortezomib maintenance therapy in patients with newly diagnosed MM. However, the therapy is associated with increased risk of adverse events. Additionally, more RCTs are needed for better understanding and determination of optimal bortezomib maintenance therapy in MM.

Introduction

Multiple myeloma (MM), a disease results from a proliferation of plasma cells and thus characterized by an elevation in immunoglobulin, is the second most frequent hematologic malignancy around the world. The median age at diagnosis is 70 years, with 37% of them younger than 65 years old, 26% aged from 65 to 74 years, and 37% beyond 75 years. The incidence rates in men are higher than in women [1,2]. The application of high dose therapy (HDT) and autologous stem cell transplantation (ASCT) as well as the advent of novel agents (e.g. immunomodulatory drugs including thalidomide and lenalidomide, and the proteasome inhibitor bortezomib) improve survival in MM but the disease still remains incurable due to high incidence of relapse. Therefore, MM maintenance therapy, a treatment given for a specific duration to maintain the response of first-line therapy and prolong survival [3], is of great interest to clinical and translational researchers.

Early trials incorporating conventional chemotherapy, interferon, or glucocorticosteroids into maintenance therapy failed to show satisfactory results due to limited survival benefit or toxicity [4]. Three meta-analyses evaluating thalidomide maintenance therapy showed progression-free survival (PFS) and overall survival (OS) benefits in transplantation-eligible patients [5,6]. However, thalidomide maintenance has several limitations, including the toxic risk of peripheral neuropathy (PN), shorter OS in patients with high-risk cytogenetics [7], and less obvious improvement in OS for elderly patients [8-11]. Clinical trials using another immunomodulatory drug lenalidomide for maintenance therapy showed...
effectiveness in response rates and PFS, but also treatment-related adverse events and potential risk of second primary malignancies (SPMs) [12,13].

Bortezomib is a boronic acid-based reversible proteasome inhibitor involving in the ubiquitin–proteasome pathway of cellular protein homeostasis. Disruption of proteasome activity results in cell growth arrest and apoptosis. Malignant plasma cells in MM produce large amount of immunoglobulins and have higher levels of proteasome activity compared with normal cells. Therefore, MM cells are more sensitive to the pro-apoptotic effects of proteasome inhibition than normal cells [14,15]. Bortezomib-based induction therapy has already shown improved PFS and OS, even for those patients with t (4;14) or renal failure [16,17], and therefore is recommended for both transplantation-eligible and transplantation-ineligible newly diagnosed MM patients [18]. This leads to further investigation for incorporating bortezomib into maintenance phase. To obtain a better understanding of the efficacy and safety of bortezomib-based maintenance therapy in newly diagnosed MM patients, we carried out this meta-analysis.

Methods
Article inclusion/exclusion criteria and quality
We searched for clinical trials in PubMed (Medline), Embase (OVID), and the Cochrane Library using key words ‘myeloma,’ ‘bortezomib OR Velcade’ and ‘maintenance OR consolidation OR continuous therapy OR continuous treatment.’ To identify eligible studies that may have been missed during the initial online search, we further examined the reference lists of relevant reviews and trials identified. The last search dated back to November, 2015.

Two investigators independently reviewed all the titles and abstracts obtained from the above search strategy. Potentially related articles were then checked in full text to identify phase III randomized controlled trials (RCTs) that compared the outcomes of bortezomib-based and non-bortezomib-based maintenance therapies in newly diagnosed MM patients. Included studies were required to report PFS and OS. Duplicated studies were regarded as one.

Two investigators independently evaluated the methodological quality (i.e. the randomization, blinding method, and completeness of follow-up) of the included studies using the Jadad scale, which could show us intuitive results by giving each study a score. Scores 3–5 and 0–2 were associated with high and low quality respectively [19]. Additionally, we checked if these studies had adopted intention to treat (ITT) analysis and reported allocation concealment, considering the neglect in Jadad scale [20].

Statistical analysis
Revman software (5.3) was used to perform all calculations related to meta-analysis. PFS was measured from the date of randomization to the time of disease progression, relapse, or death. OS was calculated as the time from randomization until death from any cause. We used hazard ratio (HR) with 95% confidence interval (95% CI) of OS and PFS outcomes for the bortezomib maintenance treatment arm over the non-bortezomib treatment arm to evaluate the efficacy. Dichotomous outcomes about adverse effects were evaluated using risks ratios (RR) with 95% CIs. Pooled results of HR and RR were calculated based on the inverse variance (IV) method and the Mantel–Haenszel (M–H) method respectively. Statistical heterogeneity was assessed using the $I^2$ test, and the DerSimonian and Laird random effects model was applied when heterogeneity was significant ($I^2>50\%$) [21,22]. The publication bias assessment was not formally carried out due to limited number of included trials.

Results
Selection of studies
We identified 498 publications through initial search and kept 22 of them for further full-text review after title and abstract screening. Nineteen publications were excluded after full-text review and only three articles [23-25] were remained to our final analysis. It is noted that two articles [24,25] providing important data from one trial were considered as one in our analysis. A phase III PETHHEMA/GEM randomized trial comparing patients who received maintenance therapy after induction and ASCT with either interferon-α or thalidomide or thalidomide plus bortezomib was included at the beginning but excluded at last due to lack of sufficient data for analysis [26]. Therefore, finally two RCTs were included in the present meta-analysis (Figure 1).

The characteristics of the two trials are summarized in Table 1. One study published in 2014 was conducted at 61 centers in Italy from May, 2006 to January, 2009 [23]. A total of 511 newly diagnosed myeloma patients who were not candidates for high-dose therapy plus stem-cell transplantation (age >65 years or with coexisting comorbidities) were randomly assigned to receive VMPT (melphalan, prednisone, bortezomib, thalidomide) induction plus VT (bortezomib, thalidomide) maintenance (254 patients) or VMP (melphalan, prednisone, bortezomib) induction without maintenance (257 patients) for 2 years. The median age is 71 years and median follow-up time is 54 months.
Figure 1. Flow diagram of study selection.

Table 1 Characteristics of studies included in the meta-analysis

| Study          | People                                      | N  | Maintenance therapy regimen | Planned maintenance duration | Median follow-up | Median PFS          |
|----------------|---------------------------------------------|----|------------------------------|------------------------------|------------------|---------------------|
| Sonneveld, P. (2013) (HOVON-65/GMMG-HD4) | Eligible, newly diagnosed, symptomatic MM Median age: 57 | 827 | Arm A (n=414): daily thalidomide 50 mg Arm B (n=413): 2-weekly bortezomib 1.3 mg/m² i.v. | 2 years          | 67 months         | N/A                 |
| Palumbo, A. (2014) (Italy) Newly diagnosed, not candidates for HDM + ASCT Median age: 71 | 511 | VT (n=254); No maintenance (n=257) | 2 years          | 54 months         | VMPT-VT: 35.3 months VMP: 24.8 months |

Abbreviations: ASCT, autologous stem cell transplantation; N/A, not available; VMP, bortezomib–melphalan–prednisone; VMPT-VT, bortezomib–melphalan–prednisone–thalidomide followed by maintenance with bortezomib–thalidomide; VT, bortezomib at a dose of 1.3 mg/m² every 15 days and thalidomide at a dose of 50 mg per day.
Table 2. Quality score of included studies applying Jadad scale

| Study                        | Randomization | Blinding | Lost/Withdrawal to follow-up | Total |
|------------------------------|---------------|----------|-----------------------------|-------|
| Sonneveld, P. (2013) (HOVON-65/GMMG-HD4) | 2             | 0        | 1                           | 3     |
| Palumbo, A. (2014) (Italy)   | 1             | 0        | 1                           | 2     |

The other study, conducted by the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the German Multicenter Myeloma Group (GMMG), was published in 2012 as full text, and its extended follow-up was reported as abstract in 2013 [24,25]. A total of 827 eligible, newly diagnosed, symptomatic MM patients were randomly assigned to VAD (vincristine, doxorubicin, dexamethasone) induction intensification with high-dose melphalan (HD) and ASCT-thalidomide maintenance (arm A, 414 patients) or PAD (bortezomib, doxorubicin, and dexamethasone) induction intensification with HD and ASCT-bortezomib maintenance for 2 years (arm B, 413 patients). The median age is 57 years and median follow-up time is 67 months.

The methodological quality of the included studies is shown in Table 2 with Jadad scale. Additionally, both studies applied ITT analysis (ITT) and neither of them offered any information about allocation concealment.

**Efficacy**

The pooled HR of PFS was 0.67 (95% CI = 0.51 to 0.87, \( P=0.003 \)), indicating a trend of PFS improvement with bortezomib maintenance. However, there was a significant heterogeneity between the two trials (\( P=0.05, I^2 = 74\% \), Figure 2). The pooled HR of OS shows the bortezomib maintenance therapy arm is superior (HR = 0.75, 95% CI = 0.63 to 0.89, \( P=0.001 \)). No significant heterogeneity was revealed between the two trials (\( P=0.56, I^2 = 0\% \), Figure 3).

**Safety**

Both trials have reported the incidence of adverse events. So, we carried out a meta-analysis measuring pooled RR to compare grade 3–4 adverse events in bortezomib maintenance therapy arm and non-bortezomib maintenance therapy arm. The analysis revealed significant differences between the two arms, and the bortezomib maintenance therapy statistically showed significantly increased risk for developing neutropenia (RR = 1.39; 95% CI = 1.08 to 1.79), PN (RR = 2.23; 95% CI = 1.38 to 3.61, \( P=0.001 \)), and cardiologic events (RR = 1.91; 95% CI = 1.12 to 3.28, \( P=0.02 \)) (Figure 4). We did not observe a significant difference in the risk of developing anemia, thrombocytopenia, infection, deep vein thrombosis and gastrointestinal (GI) symptoms between the two arms. No evidence of significant heterogeneity was revealed between the two trials.

**Discussion**

During the past decade, bortezomib has been shown to have great benefit in induction therapy of MM patients, thus leading to further clinical trials incorporating bortezomib into maintenance therapy. The objective of an ideal
Figure 4. Pooled RR of grade 3–4 adverse events comparing bortezomib maintenance therapy arm with non-bortezomib maintenance therapy arm: Different events are separately shown from subparts (a) to (h)

(a) Neutropenia, (b) thrombocytopenia, (c) anemia, (d) infection, (e) deep vein thrombosis, (f) PN, (g) cardiologic events, and (h) GI symptoms.

maintenance therapy is to improve PFS and OS with minimal toxicity and without interfering patients’ quality of life [3]. Therefore, we carried out this meta-analysis to evaluate the efficacy and safety of bortezomib maintenance in MM.

Two RCTs with a total of 1338 patients were included in our analysis. Both significant PFS and OS improvement were seen in our pooled results with bortezomib maintenance over non-bortezomib maintenance therapy. This result
indicates the benefit of bortezomib during maintenance in MM patients. Notably, according to an analysis of PFS calculated from the time of last HDM in HOVON-65/GMMG-HD4 trial, a significant difference in favor of the PAD arm was observed, indicating that although post-transplantation bortezomib and thalidomide both achieved response upgrades, bortezomib contributed more to improvement of PFS [24]. It is noted that a significant heterogeneity exists when calculating the pooled HR results of PFS. We considered that the heterogeneity comes from several sources. First, the different characteristics of individual patients in two studies could affect the evaluated results, including age, coexisting comorbidities, or MM severity. Second, both the induction and maintenance regimes differed between the two studies. Furthermore, we should take measurement bias into consideration.

Regarding the safety of applying bortezomib during maintenance, our analysis revealed significant differences between the two arms. Higher incidence of neutropenia, cardiologic events, and PN were observed in patients of the bortezomib maintenance group. Consistent with previous reports, PN is the most frequent adverse effect, which could be managed by dose adjustment, subcutaneous administration, and decreasing the frequency of administration of bortezomib (Millennium Pharmaceuticals, Inc. VELCADE® (bortezomib) official website http://www.velcade.com/Treatment-with-velcade/Possible-side-effects (2016)) [27]. As for supplementary specification, newly developed grade 3–4 PN occurred in 8% of patients during thalidomide maintenance and 5% of patients during bortezomib in HOVON-65/GMMG-HD4 trial, and for VMPT-VT arm in the study of Palumbo et al. [23] containing both bortezomib and thalidomide during the incidence of PN was 11% [24].

However, conflicting results have also been reported in other studies. A phase III PETHEMA/GEM randomized trial compared bortezomib/thalidomide, thalidomide, and Alfa2b-interferon as maintenance therapy after stem-cell transplantation for MM patients for a median follow-up of 34.9 months. The results showed that the PFS was significantly longer with TV compared with the other two arms (P=0.0009), but there was no significant difference in OS among the three arms [26]. In the UPFRONT study with patients’ median age higher than 70 years comparing VD, VTD, and VMP induction followed by bortezomib maintenance, only 5% of patients experienced grade ≥3 PN during maintenance, without adverse influence on patients’ quality of life [28,29].

In addition, the GEM2005MAS65 randomized trial investigated by the Spanish myeloma group compared maintenance therapy with bortezomib plus thalidomide (VT) or prednisone (VP) in elderly untreated myeloma patients, who had previously received induction with bortezomib, melphalan, and prednisone or bortezomib, thalidomide, and prednisone. The results showed an increase in complete response (CR) rate, remarkably long PFS, and acceptable toxicity, suggesting clinical benefit of bortezomib-based maintenance therapy [30]. Another analysis of the phase III HOVON-65/GMMG-HD4 trial showed that the known adverse impact of deletion 17p (del17p13) can be markedly reduced by incorporating bortezomib into the treatment and may be important for the long-term management of patients with this high-risk feature [31].

In view of the facts mentioned above, we suggest that more RCTs are needed to help us further understand the efficacy and safety of bortezomib maintenance in MM with different characteristics of patients and diverse drug combination regimes.

Our analysis was carried out through a standardized process, but it also has some limitations. First, only two studies were included in our analysis after comprehensive search and careful selection. One study without sufficient data was excluded [26]. Second, possible publication bias can affect our interpretation. Third, the Italian study didn’t report proper techniques for randomized allocation. And in both studies, randomized allocation was applied only before induction but not maintenance therapy, which led to difficulty in making a clear dissection of the role of bortezomib maintenance therapy. Fourth, due to the paucity of studies, we couldn’t perform a sensitivity analysis. In addition, variant characteristics of patients enrolled in the two RCTs, different study designs and varied length of follow-up time may also influence the statistical power of pooled outcomes.

In conclusion, our meta-analysis showed significant OS and PFS benefits of bortezomib maintenance therapy in patients with newly diagnosed MM. However, the increased risk of adverse events warrants serious consideration and adequate measures. Future RCTs are needed for better understanding and optimizing bortezomib maintenance therapy in MM.

**Author Contribution**

C.-Y.S, J.-Y.L., and Y.H. designed this meta-analysis. C.-Y.S. and J.-Y.L. conducted it and wrote the main manuscript text. J.-Y.L., Z.-B.C., L.Z., and L.C. prepared all the figures. All authors reviewed the manuscript.

**Competing Interests**

The authors declare that there are no competing interests associated with the manuscript.
Funding

This work was supported by the National Natural Science Foundation of China [grant number 81272625 (to C.-Y.S)]; National Natural Science Funds for Youth Science Fund Project [grant number 81302042 (to C.-Y.S)]; the Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST (to Y.H.); and the Clinical Research Physician Program of Tongji Medical College, HUST (to Y.H.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abbreviations

ASCT, autologous stem cell transplantation; CI, confidence interval; HDM, high-dose melphalan; HDT, high dose therapy; HR, hazard ratio; IV, inverse variance; MM, multiple myeloma; OS, overall survival; PFS, progression-free survival; PN, peripheral neuropathy; RR, risks ratios; SPM, second primary malignancy.

References

1. Palumbo, A. and Anderson, K. (2011) Multiple myeloma. N. Engl. J. Med. 364, 1046–1060
2. Jemal, A., Siegel, R., Xu, J. and Ward, E. (2010) Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300
3. Mihelic, R., Kaufman, J.L. and Lonial, S. (2007) Maintenance therapy in multiple myeloma. Leukemia 21, 1150–1157
4. Ludwig, H., Durie, B.G., McCarthy, P., Palumbo, A., San, M.J., Barlogie, B. et al. (2012) IMWG consensus on maintenance therapy in multiple myeloma. Blood 119, 3003–3015
5. Nooka, A.K., Behera, M., Boise, L.H., Kaufman, J.L., Watson, M. and Lonial, S. (2011) Thalidomide as maintenance therapy in multiple myeloma (MM) improves progression free survival (PFS) and overall survival (OS): a meta-analysis. ASH Annu. Meet. Abstr. 118, 1855
6. Hahn, A., Lilientfeld, T.M. and Heteren, P. (2011) Improved progression-free and overall survival with thalidomide added to autologous stem cell transplantation in multiple myeloma: a meta-analysis of five randomized trials. Haematologica 96, 884
7. Morgan, G.J., Gregory, W.M., Davies, F.E., Bell, S.E., Szubert, A.J. et al. (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119, 7–15
8. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V. et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825–831
9. Wijermans, P., Schaafsma, M., Termorshuizen, F., Ammerlaan, R., Wittebol, S. et al. (2010) Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 45 Study. J. Clin. Oncol. 28, 3160–3166
10. Waage, A., Ginsing, P., Fayers, P., Ablidgaard, N., Ahlberg, L. et al. (2010) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116, 1405–1412
11. Beksar, M., Hazmard, R., Firtal-Tuglular, T., Ozdogu, H., Aydogdu, I., Konuk, N. et al. (2011) Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur. J. Haematol. 86, 16–22
12. Yang, B., Yu, R.L., Chi, X.H. and Lu, X.C. (2013) Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One 8, e64354
13. Palumbo, A., Bringhen, S., Kumar, S.K., Lupparelli, G., Usmani, S., Waage, A. et al. (2014) Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 15, 333–342
14. Adams, J. (2004) The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4, 349–360
15. Yang, H., Zonder, J.A. and Dou, Q.P. (2009) Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin. Investig. Drugs 18, 957–971
16. Avet-Loiseau, H., Leleu, X., Rousset, M., Moreau, P., Guerin, C.C., Caillot, D. et al. (2010) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28, 4630–4634
17. McCarthy, P.L., Einsele, H., Attal, M. and Giralt, S (2014) The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Expert Rev. Hematol. 7, 55–66
18. Rollig, C., Knop, S. and Bornhauser, M. (2015) Multiple myeloma. Lancet 385, 2197–2208
19. Schulz, K.F., Altman, D.G. and Moher, D. (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann. Intern. Med. 152, 736–737
20. Hartling, L., Ospina, M., Liang, Y., Dryden, D.M., Hooton, N., Krebs-Seida, J. et al. (2009) Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. Br. Med. J. 339, b4012
21. Higgins, J.P., Thompson, S.G., Deeks, J.J. and Altman, D.G. (2003) Measuring inconsistency in meta-analyses. Br. Med. J. 327, 557–560
22. DerSimonian, R. and Laird, N (1986) Meta-analysis in clinical trials. Control Clin. Trials 7, 177–188
23. Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V. et al. (2014) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J. Clin. Oncol. 32, 634–640
24. Sonneveld, P., Schmidt-Erf, I., van der Holt, B., El Jarari, J., Bertsch, U., Salwender, H. et al. (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J. Clin. Oncol. 30, 2946–2955
25. Sonneveld, P., Scheid, C., Van Der Holt, B., El Jarari, J., Bertsch, U., Salwender, H. et al. (2013) Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma: Extended follow-up of the HOVON-65/GMMG-HD4 trial. Blood 21, 122
26 Rosinnol, L., Albert, O., Ana, I.T., Dolores, H., Javier, L.J., Javier, D.L.R. et al. (2012) Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide vs. thalidomide vs. Alfa2b-interferon: Final results of a phase III PETHEMA/GEM randomized trial. *Blood (ASH Ann. Meeting Abstr.*) 120, Abstract 334

27 Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M. et al. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. *Lancet Oncol.* 12, 431–440

28 Niesvizky, R., Flinn, I.W., Rifkin, R.M., Gabrail, N.Y., Charu, V., Clowney, B. et al. (2010) Phase 3b UPFRONT Study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients. *ASH Ann. Meeting Abstr.* 116, 619

29 Niesvizky, R., Flinn, I.W., Rifkin, R.M., Gabrail, N.Y., Charu, V., Clowney, B. et al. (2011) Patient-reported quality of life (QoL) in elderly, newly diagnosed multiple myeloma (MM) patients receiving bortezomib-based combinations: results from all randomized patients in the community-based, Phase 3b UPFRONT Study. *ASH Ann. Meeting Abstr.* 118, 1864

30 Mateos, M.V., Oriol, A., Martinez-Lopez, J., Gutierrez, N., Teruel, A.I., Lopez De La Guia, A. et al. (2012) Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. *Blood* 120, 2581–2588

31 Neben, K., Lokhorst, H.M., Jauch, A., Bertsch, U., Hielscher, T., van der Holt, B. et al. (2012) Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. *Blood* 119, 940–948